Monoclonal antibodyFDA-approvedFirst-line
Ipilimumab
How it works
Blocks CTLA-4, a protein that normally helps cancer cells evade the immune system, allowing the immune system to attack cancer cells.
Cancer types
Efficacy
Studies show that around 20% of patients achieved an objective response, with a median overall survival of approximately 11.4 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing New Treatments for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Testing IL2 and Immunotherapy in Advanced Melanoma Patients | Melanoma | phase-2 | — | Source → |
| Evaluating Nivolumab and Ipilimumab in Combination with Chemotherapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Breast Cancer and Solid Tumors | Breast Cancer | phase-1 | — | Source → |
| Testing Fianlimab, Cemiplimab, and Ipilimumab in Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Nivolumab and Ipilimumab with Radiation in Advanced Rectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Nivolumab and Ipilimumab Trial | Lung Cancer | phase-2 | — | Source → |
| Testing Tocilizumab with Immunotherapy for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Immunotherapy Shows Promise for Rare Ovarian and Cervical Cancers | Leukemia | phase-2 | The overall response rate was 9.38%, with two complete responses that are ongoing at >3 years and one partial response. | Source → |
| Combining Immunotherapy for Advanced Anal Cancer | Colorectal Cancer | phase-2 | The median progression-free survival was 2.9 months for nivolumab and 3.7 months for nivolumab plus ipilimumab. | Source → |
| Immunotherapy Response Predicted by Low Tumor Mutation Burden and PD-L1 Expression | Melanoma | observational | — | Source → |
| Melanoma Study Examines Vaccine Combination with Immunotherapy | Melanoma | phase-2 | Objective response rates were 59.7% and 59.2% in the two treatment arms. | Source → |
| Combination Treatment Shows Promise for Rare Gynecological Cancers | Ovarian Cancer | phase-2 | The overall objective response rate was 54% (95% CI, 35-71), with 3 (12%) complete responses and 12 (42%) partial responses. | Source → |
| Cost-effectiveness of dual immunotherapy for lung cancer | Lung Cancer | phase-3 | Nivolumab plus ipilimumab provided an incremental gain of 1.11 and 0.96 QALYs over chemotherapy in the USA and China, respectively. | Source → |
| Comparing Two Ways to Give Cancer Treatment | Melanoma | phase-2 | — | Source → |
| Combining treatments improves survival for ovarian cancer patients | Ovarian Cancer | meta-analysis | PD1/PDL1 inhibitors plus chemotherapy and PD1/PDL1 inhibitors plus ipilimumab showed the greatest progression-free survival (PFS) benefit (hazard ratio (HR) = 0.82, 95% confidence interval [CI]: 0.52-1.07; HR = 0.82, 95% CI:0.51-1.33) and overall survival (OS) (HR = 0.85, 95% CI:0.64-1.14; HR = 0.83, 95% CI:0.45-1.54). | Source → |
| Rare Side Effects of Cancer Treatment | Melanoma | observational | — | Source → |
| IDO Expression in Melanoma Treated with Ipilimumab | Melanoma | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.